REG - Oncimmune Hldgs PLC - Contract Win

Oncimmune HoldingsAnnouncement

02/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB4184Ca&default-theme=true

RNS Number : 4184C  Oncimmune Holdings PLC  02 September 2024

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Additional contract win with Top 10 Pharma Company

 

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine, is pleased to announce another new contract win with a Top 10 Global Pharma Company.

 

Further to its announcement on 9 August 2024 of an agreement for a new
contract with a major global pharmaceutical company with a value of at least
US$1.5M, Oncimmune has now agreed a new project with another major
pharmaceutical company, with the contract value of US$0.7m.  The contract is
with a customer for whom Oncimmune is already a preferred supplier under a
long-term master services agreement.  The project focuses on a rare immune
related disease, an area in which Oncimmune has considerable experience, and
aims to identify biomarkers related to disease or disease subtype, organ
involvement and clinical response.  It will use an array of over 1,000
antigens run on Oncimmune's high-throughput, bead-based system.  Oncimmune
will analyse over 500 samples, many of which are already held by Oncimmune.

 

Martin Gouldstone, CEO of Oncimmune said:

 

"I continue to be pleased with the commercial progress we are making,
especially in terms of the increasing scale of the projects we are winning
with major customers.  Our recent wins show that our strategy is working and
I am confident that we are in a strong position to meet our targets for FY24
and reach profitability in FY25."

 

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com (mailto:contact@oncimmune.com)

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks, Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

 

Zeus (Joint Broker)

Dominic King, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

This Announcement contains inside information for the purposes of Article 7
of the Market Abuse Regulation No. 596/2014 as retained as part of UK law
by virtue of the European Union (Withdrawal) Act 2018 as
amended ("EUWA") and as it may be modified from time to time by or under
domestic law including, but not limited to, by the Market Abuse (Amendment)
(EU Exit) Regulations 2019/310). Upon the publication of this Announcement,
this inside information is now considered to be in the public domain.

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

 

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUARKRSSUKRAR